Gilead Sciences | GILD - Marktkapitalisierung

Aktienkurs
130.40
Täglich Wechseln
-3.24 -2.42%
Monatlich
-5.68%
Jährlich
26.39%
Q2 Prognose
127.61




Marktkapitalisierung Veränderung Datum
AbbVie USD 403.83B 5.2B 2025-12
Agios Pharmaceuticals USD 1.59B 745M 2025-12
ALKERMES USD 4.62B 333M 2025-12
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amgen USD 176.25B 24.32B 2025-12
Biogen USD 25.82B 5.28B 2025-12
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Bristol-Myers Squibb USD 109.81B 18.01B 2025-12
Coherus Biosciences USD 172M 19M 2025-12
Eli Lilly USD 1.02T 293.84B 2025-12
Gilead Sciences USD 166.62B 14.34B 2026-04
GlaxoSmithKline GBP 74.36B 10.31B 2025-12
Glaxosmithkline GBP 99.93B 13.05B 2025-12
Incyte USD 19.39B 2.83B 2025-12
J&J USD 561.65B 17.5B 2026-04
Merck USD 261.26B 51.62B 2025-12
Neurocrine Biosciences USD 14.14B 218M 2025-12
Novartis USD 292.21B 26.55B 2025-12
Pfizer USD 141.57B 6.48B 2025-12
PTC Therapeutics USD 5.26B 844M 2026-04
Regeneron Pharmaceuticals USD 81.12B 21.53B 2025-12
Sanofi EUR 101.43B 1.16B 2026-04
Sarepta Therapeutics USD 2.26B 238M 2025-12
United Therapeutics USD 20.98B 2.02B 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12